Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Spatiotemporal Mapping of Immune Cell Behavior in Glioblastoma

Objective

Immune cells, particularly cytotoxic T lymphocytes, are highly motile capable of infiltrating and eliminating tumors—a feature driving the recent revolution of immunotherapies. Yet a common barrier is the failure of T cells to infiltrate tumors, with local peritumoral and perivascular arrest as a key hurdle. Efforts to overcome this, such as decades of targeting of major tumor-supportive cytokines have yielded limited breakthroughs. A likely reason is methodological bias: most studies profile bulk tissues at single endpoints, detecting only sustained, widespread signals while overlooking the transient, localized interactions that may drive T-cell arrest.
I propose to develop spatially and temporally resolved transcriptomic technology to map immune cell interactions and behavior over time, and apply it to study immune dysfunction in glioblastoma (GBM), a lethal brain tumor. I recently developed Zman-seq, the first in vivo single-cell method to capture immune cell state transitions over time and their driving signals. Zman-seq revealed that immune reprogramming occurs rapidly within just a day after infiltration. To resolve the early local interactions driving this, we will combine spatial data with Zman-seq, and measure T-cell motility as a functional readout. First, to pinpoint the early niches, I will combine Zman-seq timestamps with spatial transcriptomics and describe how immune cells occupy cellular niches over time. Next, to study T-cell behavior within these niches, I will directly visualize T-cell motility via intravital microscopy and register in vivo tracks to ex vivo spatial transcriptomics, creating a new approach—VideoTranscriptomics. Applied in a GBM model, this will reveal the sequence of niches immune cells traverse, and pinpoint early, targetable checkpoints that drive T-cell arrest and immunotherapy resistance.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2026-STG

See all projects funded under this call

Host institution

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Net EU contribution
€ 1 484 173,00
Address
IM NEUENHEIMER FELD 280
69120 Heidelberg
Germany
Region
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Activity type
Research Organisations
Links
Total cost
€ 1 484 173,75

Beneficiaries (1)